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Abstract
Objective: CD4þ T lymphocyte count remains the most common biomarker of immune status
and disease progression in human immunodeficiency virus (HIV)-positive individuals.
VISITECTV
R
CD4 is an instrument-free, low-cost point-of-care CD4 test with a cut-off of 350
CD4 cells/lL. This study aimed to evaluate VISITECTVR CD4 test’s diagnostic accuracy.
Methods: Two hundred HIV-positive patients attending a tertiary HIV centre in South India were
recruited. Patients provided venous blood for reference and VISITECTV
R
CD4 tests. An additional





mance in identifying individuals with CD4 counts 350 cells/lL was assessed by calculating
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sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) taking
flow cytometry as the reference.
Results: The overall agreement between VISITECTV
R
CD4 and flow cytometry was 89.5% using
venous blood and 81.5% using finger-prick blood. VISITECTV
R
CD4 showed better performance
using venous blood [sensitivity: 96.6% (95% confidence interval: 92.1%–98.9%), specificity: 70.9%
(57.1%–82.4%), PPV: 89.7% (83.9%–94.0%) and NPV: 88.6% (75.4%–96.2%)] than using finger-
prick blood [sensitivity: 84.8% (77.9%–90.2%), specificity: 72.7% (59.0%–83.9%), PPV: 89.1%
(82.7%–93.8%) and NPV: 64.5% (51.3%–76.3%)].
Conclusion: VISITECTV
R
CD4 performed well using venous blood, demonstrating its potential
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Introduction
CD4þ T cell count is an indicator of
immune function and remains an important
tool to assess human immunodeficiency
virus (HIV) disease stage, progression, and
prognosis. HIV infection leads to depletion
of CD4þ T cells in gut-associated lymphoid
tissue with subsequent reductions of circu-
lating CD4þ lymphocytes in the peripheral
blood.1 Current WHO guidelines recom-
mend lifelong antiretroviral therapy
(ART) regardless of CD4þ cell count, with
analysis of viral load as the preferred mon-
itoring approach.2 However, assessment of
CD4þ count at diagnosis can improve early
ART initiation and retention.3 For patients
with higher CD4þ counts (>350 cells/lL),
longer term ART adherence may be
enhanced if the patient is prepared for a
few weeks through ART HIV education
and counselling until ART readiness is con-
firmed. Previous studies have shown that
access to CD4þ testing following diagnosis
could improve ART initiation and
retention4,5 and predict treatment
outcomes: low CD4þ counts (<350 cells/
mL) were associated with increased risk of
non-adherence.6 In resourced-constrained
setting where universal treatment is not fea-
sible, ART initiation should be prioritised
in HIV-positive individuals with advanced
disease or CD4þ counts of less than 350
cells/mL2. Standard laboratory based
CD4þ cell measurement techniques require
an initial investment in flow cytometric
technology, infrastructure requirements
and associated reagent; these can be unaf-
fordable or unavailable in resource-
constrained settings, limiting patient access
to CD4þ testing.7 Point-of-care (POC)
CD4þ testing has the potential to overcome
challenges of traditional laboratory based
approaches and can provide reliable results
under field conditions.8
The lateral flow-based VISITECTVR CD4
rapid test (Omega Diagnostics, UK) is a
promising tool to guide treatment decisions
at the POC without extensive training or
sophisticated equipment. This test provides
a semi-quantitative determination of CD4
counts with a cut-off of 350 cells/mL.
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The schematic and testing procedures for
VISITECTVR CD4 have been reported
elsewhere.9
This study aimed to evaluate the diag-
nostic accuracy of VISITECTVR CD4 in
detecting CD4þ counts less than 350 cells/
mL compared with the gold standard, flow
cytometry.
Materials and methods
This was a prospective diagnostic accuracy
study. HIV-positive patients attending the
HIV clinic at the YRG Centre for AIDS
Research Education (YRG CARE),
Chennai, India, were consecutively
recruited between May and September
2017. No inclusion or exclusion criteria
were applied beyond confirmation of HIV
infection. All study participants aged 15
years and older provided written informed
consent prior to enrolment. The study was
approved by the YRG CARE institutional
ethics committee. All procedures were con-
ducted in accordance with the principles
laid out in the 1964 Declaration of
Helsinki and its later amendments
An expected sensitivity of 60% was
reported in earlier studies.9,10 CD4þ cells
were enumerated from all specimens using
both VISITECTVR CD4 and flow cytometry.
Staff were trained to perform the
VISITECTVR CD4 test by experienced oper-
ators from Omega Diagnostics.
Limited sociodemographic information
was collected using previously developed
data collection forms to capture partici-
pants’ age and gender. A unique study ID
was assigned to each participant to link
sociodemographic information with diag-
nostic test results. A trained phlebotomist
collected a finger-prick blood sample with
a lancet and the venous whole blood speci-
mens were collected using a 2-mL vacu-
tainer tube (Becton Dickinson, Franklin
Lakes, NJ, USA) containing ethylenedi-
aminetetraacetic acid.
For each participant, four CD4þ tests
were performed in parallel at the YRG
CARE laboratory by trained lab techni-
cians: (i) VISITECTVR CD4 from finger-
prick blood (performed and documented
by one lab technician); (ii)
VISITECTVR CD4 from venous blood (two
tests by two lab technicians); and (iii) a ref-
erence flow cytometric CD4þ count using
FlowCARE PLG CD4þ reagent and a
NAVIOS flow cytometer (Beckman
Coulter, Brea, CA, USA) performed using
the same venous sample used for
VISITECTVR CD4. The output in the
VISITECTVR CD4 test was either above ref-
erence (AR; CD4þ> 350 cells/mL) or below
reference (BR; CD4þ cells< 350 cells/mL).
Finger-prick testing was performed at the
POC and the results were recorded immedi-
ately. Venous specimens were transported
to the laboratory in gel-packed
containers and maintained at 20–25C
before testing. The testing laboratory was
in the second level of the same block
as the specimen collection centre.
All CD4þ assessments were performed
within 6 hours of sample collection.
VISITECTVR CD4 tests were performed and
results were recorded independently and
blinded from the results of other testing
procedures. The flow cytometry results
were used for patient management and the
VISITECTVR CD4 test results did not influ-
ence clinical management of the patients
participating in this study.
The diagnostic performance of
VISITECTVR CD4 in identifying samples
with CD4þ counts less than 350 cells/mL
was assessed by calculating sensitivity, spe-
cificity, positive predictive value (PPV) and
negative predictive value (NPV). Analyses
were performed using STATA statistical
software version 15.0 (Stata Corp, College
Station, TX, USA). Findings were reported
according to the STARD reporting
guidelines.11
Vidhyavathi et al. 3
Ethical approval and informed consent
All procedures were in accordance with the
ethical standards of the YRG CAREs insti-
tutional review board, as well as the 1964
Declaration of Helsinki and its later amend-
ments. Informed consent was obtained
from all participants included in the study.
Results
Demographic characteristics of study
participants
Among the 200 HIV-positive patients
recruited to the study, 123 were men
(61.5%) and 77 were women (38.5%). The
median age was 40 years (interquartile
range [IQR]: 36–47.5 years; range: 15–68
years). CD4 counts ranged from 3 to 1264
cells/lL with a median of 222 cells/lL
(IQR: 86.5–375 cells/lL). One hundred
and forty-five patients (72.5%) had CD4
counts of 350 cells/lL and 55 (27.5%)
had CD4 counts of >350 cells/lL according
to the reference test (flow cytometry).
Twenty-four (12%) participants had
CD4þ counts between 300 and 400 cells/
lL, of whom 14 and 10 had CD4 counts
of 300–350 and 351–400 cells/lL, respec-
tively. One participant had a CD4 count
of exactly 350 cells/lL. There were no
inconclusive reference or VISITECTVR CD4
test results.
VISITECTVR CD4 from finger-prick blood
The disposable VISITECTVR CD4 test uses
30 mL of whole blood and provides semi-
quantitative results at a 350 cells/mL cut-
off within 40 minutes (Figure 1). The
visual interpretation of AR and BR for
finger-prick blood samples using the
VISITECTVR CD4 test was compared for
agreement with the quantitative results of
flow cytometry. The overall agreement
was 81.5% (163/200; Figure 2). The
sensitivity, specificity, PPV and NPV of
VISITECTVR CD4 from finger-prick blood
were 84.8% [95% confidence interval (CI):
77.9% to 90.2%], 72.7% (59.0% to 83.9%),
89.1% (82.7% to 93.8%) and 64.5%
(51.3% to 76.3%), respectively (Table 1A).
The performance characteristics of
VISITECTVR CD4 excluding the 24 speci-
mens with CD4þ counts between 300 and
400 cells/lL are given in Table 1B for both
finger-prick and venous blood samples.
VISITECTVR CD4 from venous blood
The overall agreement between
VISITECTVR CD4 from venous blood and
flow cytometry was 89.5% (179/200;
Figure 3). The sensitivity, specificity, PPV
and NPV of VISITECTVR CD4 were 96.6%
(95% CI: 92.1% to 98.9%), 70.9% (95%
CI: 57.1% to 82.4%), 89.7% (95% CI:
83.9% to 94.0%) and 88.6% (95% CI:
75.4% to 96.2%), respectively (Table 1A).
A second (duplicate) VISITECTVR CD4 test
from venous blood gave similar results
(Figure 3 & Table 1A). One specimen
result was invalid because of a missed con-
trol line and this was not included in the
analysis.
Discussion
In this study, we assessed the diagnostic
performance of VISITECTVR CD4, an
affordable, equipment-free test for semi-
quantitative measurement of CD4 counts
at the POC. We compared the results of
the VISITECTVR CD4 test using both
finger-prick and venous blood samples
with those of the gold standard (flow
cytometry) using a cut-off of 350 cells/mL.
We found that the results of the
VISITECTVR CD4 test agreed well with
those of the reference test, with an overall
agreement of 81.5% for finger-prick blood
samples and 89.5% for venous blood
samples.
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We observed better performance of the
VISITECTVR CD4 test using venous blood
compared with finger-prick blood samples.
This was reflected in a higher sensitivity in
detecting samples with 350 cells/mL
[96.6% (95% CI: 92.1% to 98.9%) vs
84.8% (95% CI: 77.9% to 90.2%)]. This
result corroborates those of a study con-
ducted in South Africa showing superior
performance of VISITECTVR CD4 using
Index test; n=200
VISITECT® CD4 ≤350 cells/μL;
n=138





































Figure 2. Flow diagram of 200 VISITECTV
R
CD4 tests performed using 200 finger-prick blood samples




Figure 1. Interpretation of VISITECTV
R
CD4 test results.
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venous blood (sensitivity 81.7%, 95% CI:
72.3% to 91.1%) compared with finger-
prick blood (sensitivity 60.7%, 95% CI:
45.0% to 76.3%).9 It is notable, however,
that the sensitivity of VISITECTVR CD4
reported here was significantly higher than
that reported in the South African study
using both sample types (96.6% vs 81.7%
for venous blood and 84.8% vs 60.7% for
finger-prick blood). This improved perfor-
mance could result in part from the
laboratory-based design and minor
improvements to the test kit used in the pre-
sent study. Another potential explanation
for this difference was the distribution of
CD4þ counts in our study population.
A moderate proportion (24.5%) of patients
had CD4þ counts between 250 and 450
cells/mL and the majority of samples
(75.5%) fell outside this range. There may
also be differences in the frequency of low
CD4þ counts (<350 cells/mL) between
Indian and African populations. Our
findings further confirm that the
VISITECTVR CD4 test using venous blood
could serve as a reliable alternative for mea-
surement of CD4 counts, enabling accurate,
timely clinical decision making at the POC.
The option to use finger-prick blood
samples makes the VISITECTVR CD4 test
particularly suitable for health care workers
in settings where venipuncture may not be






CD4 test (visual reading)
Venous blood Finger-prick blood
350 cells/mL >350 cells/mL 350 cells/mL >350 cells/mL
350 cells/mL (145) 140 5 123 22
>350 cells/mL (55) 16* 39* 15 40
Sensitivity, % (95%CI) 96.6% (92.1% to 98.9%) 84.8% (77.9% to 90.2%)
Specificity, % (95%CI) 70.9% (57.1% to 82.4%) 72.7% (59.0% to 83.9%)
PPV, % (95%CI) 89.7% (83.9% to 94.0%) 89.1% (82.7% to 93.8%)
NPV, % (95%CI) 88.6% (75.4% to 96.2%) 64.5% (51.3% to 76.3%)
*The results of the second (duplicate) VISITECTV
R
CD4 test using venous blood were 17 and 38 participants with350 and
>350 cells/lL, respectively, giving a sensitivity of 96.6% (92.1% to 98.9%), a specificity of 69.1% (55.2% to 80.9%), a PPV of
89.2% (83.2% to 93.6%) and a NPV of 88.4% (74.9% to 96.1%).
Table 1B. Performance characteristics of the VISITECTV
R





CD4 test (visual reading)
Venous blood Finger-prick blood
350 cells/mL >350 cells/mL 350 cells/mL >350 cells/mL
<300 cells/mL (131) 128 3 115 16
>400 cells/mL (45) 8 37 11 34
Sensitivity, % (95%CI) 97.7% (93.5% to 99.5%) 87% (80.9% to 92.9%)
Specificity, % (95%CI) 82.2% (67.9% to 92.0%) 75.6% (60.5% to 87.1%)
PPV, % (95%CI) 94.1% (89.5% to 96.8%) 91.3% (86.2% to 94.6%)
NPV, % (95%CI) 92.5% (80.0% to 97.4%) 68.0% (56.6% to 77.6%).
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feasible. Whilst the high sensitivity (and
PPV) of VISITECTVR CD4 using a 350-
cells/mL cut-off and venous blood is encour-
aging, the lower specificity (and NPV) using
finger-prick samples could be considered a
limitation. Up to 35% (22/62) of patients
had false negative results (CD4 count
>350 cells/mL by VISITECTVR CD4 using
finger-prick blood but were demonstrated
to have 350 CD4 cells/mL by flow cytom-
etry). These patients (22/145 or 15% of
patients with CD4 counts 350 cells/lL
by flow cytometry) would not be given
appropriate care if clinical decision relating
to their immunological status and disease
progression stage was based on
VISITECTVR CD4 test results from finger-
prick blood.
Differences in the diagnostic perfor-
mance of POC CD4 tests using finger-
prick compared with venous blood have
been previously reported.12,13 In spite of
the laboratory challenges in resource-poor
settings14 studies have shown that absolute
CD4 counts and CD4 percentages obtained
from capillary and venous blood are gener-
ally in agreement.15,16 Thus, researchers
have speculated that test operator errors17
or variation in sample volume collection18
may be the causes of sub-optimal diagnostic
performance of POC CD4 tests using
finger-prick or capillary blood.
In this study, the VISITECTVR CD4 test
was performed by trained lab technicians
using provided capillary tubes for sample
collection in a clinical laboratory setting.
This design minimises the likelihood of
test operator errors and/or sample collec-
tion errors as contributing factors to sub-
optimal performance of the test using
finger-prick blood. The results of duplicate












































Figure 3. Flow diagram of 200 VISITECTV
R
CD4 tests performed using 200 venous blood samples reported
as per the STARD statement.11 *Results of the second (duplicate) VISITECTV
R
CD4 test using venous blood.
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test operators confirmed that the
VISITECTVR CD4 test performed reliably
using venous blood. However, the single
finger-prick test by a third test operator
did not allow head-to-head comparison
between the venous and finger-prick tests
results. Thus, test operator variation could
not be ruled out as a source of differences
in the diagnostic performance of
VISITECTVR CD4 test for different sample
types. Research into the potential causes
of the differential accuracy of the
VISITECTVR CD4 test using finger-prick
blood samples is needed to guide implemen-
tation strategies, especially because finger-
prick blood sampling would be the
preferred method for POC CD4 testing.19
Conclusions
CD4 testing remains an important part of
HIV treatment and care. The strong perfor-
mance of VISITECTVR CD4 using venous
blood confirms its potential for decentrali-
sation of CD4 testing services in resource-
constrained settings. Further improvements
in the diagnostic performance of
VISITECTVR CD4 using finger-prick blood
are needed to maximise the potential
impact of this test when deployed in
the field.
Authors’ contributions
PB, SSS, DAA, CMM and SMC conceived and
designed the analysis. VV, KK and PN collected
the data. EV, JF, VV and SI performed data
analysis. VV, SI, PB, SL and MDP wrote the
paper. All authors critically reviewed the manu-
script and approved the final version.
Acknowledgements
The authors would like to acknowledge the clin-
ical and laboratory staff who assisted in this
study as well as the men and women who
agreed to participate in the study.
Declaration of conflicting interest
The study was funded by Omega Diagnostics.
SMC and DAA developed the VISITECTVR
CD4 device at the Burnet Institute in Australia,
which owns the intellectual property associated
with the VISITECTVR CD4 test. SL and MDP are
employed by the Burnet Institute but were not
involved in test development. JF and CMM are
employees of Omega Diagnostics, which is the
manufacturer of the VISITECTVR CD4 test.
They were not involved in the study processes
and implementation other than in study design
and training of the test operators.
Funding
This study was supported by Omega Diagnostics
(Asia) Pvt, Ltd., Mumbai, India. Omega
Diagnostics provided the VISITECTVR CD4 tests
free of charge for study purposes. The authors
gratefully acknowledge the support of the
Victorian Operational Infrastructure Support
Program received by the Burnet Institute.
Funding was provided by the National Health
and Medical Research Council of Australia






1. Ford N, Meintjes G, Pozniak A, et al. The
future role of CD4 cell count for monitoring
antiretroviral therapy. Lancet Infect Dis
2015; 15: 241–247.
2. World Health Organization. Consolidated
guidelines on the use of antiretroviral drugs
for treating and preventing HIV infection:
recommendations for a public health
approach, https://apps.who.int/iris/handle/
10665/208825 (2016, accessed 16 July 2019).
3. Govindasamy D, Meghij J, Kebede Negussi
E, et al. Interventions to improve or facili-
tate linkage to or retention in pre-ART
(HIV) care and initiation of ART in low-
8 Journal of International Medical Research
and middle-income settings–a systematic
review. J Int AIDS Soc 2014; 17: 19032.
4. Desai MA, Okal DO, Rose CE, et al. Effect
of point-of-care CD4 cell count results on
linkage to care and antiretroviral initiation
during a home-based HIV testing campaign:
a non-blinded, cluster-randomised trial.
Lancet HIV 2017; 4: e393–e401.
5. Wynberg E, Cooke G, Shroufi A, et al.
Impact of point-of-care CD4 testing on link-
age to HIV care: a systematic review. J Int
AIDS Soc 2014; 17: 18809.
6. Fonsah JY, Njamnshi AK, Kouanfack C,
et al. Adherence to antiretroviral therapy
(ART) in Yaounde-Cameroon: Association
with opportunistic infections, depression,
ART regimen and side effects. PLoS One
2017; 12: e0170893.
7. Zachariah R, Reid SD, Chaillet P, et al.
Viewpoint: Why do we need a point-of-
care CD4 test for low-income countries?
Trop Med Int Health 2011; 16: 37–41.
8. Pham MD, Agius PA, Romero L, et al.
Performance of point-of-care CD4 testing
technologies in resource-constrained set-
tings: A systematic review and meta-analy-
sis. BMC Infect Dis 2016; 16: 592.
9. Luchters S, Technau K, Mohamed Y, et al.
Field performance and diagnostic accuracy
of a Low-cost instrument-free point-of-care
CD4 test (VISITECTVR CD4) performed by
different health worker cadres among preg-
nant women. J Clin Microbiol 2019; 57:
e01277–18. Epub ahead of print February
2019. DOI: 10.1128/JCM.01277-18.
10. Hajian-Tilaki K. Sample size estimation in
diagnostic test studies of biomedical infor-
matics. J Biomed Inform 2014; 48: 193–204.
11. Bossuyt PM, Reitsma JB, Bruns DE, et al.
STARD 2015: an updated list of essential
items for reporting diagnostic accuracy stud-
ies. BMJ 2015; 351: h5527.
12. Pham MD, Agius PA, Romero L, et al.
Acceptability and feasibility of point-of-
care CD4 testing on HIV continuum of
care in low and middle income countries: a
systematic review. BMC Health Serv Res
2016; 16: 343.
13. Diaw PA, Daneau G, Coly AA, et al.
Multisite evaluation of a point-of-care
instrument for CD4(þ) T-cell enumeration
using venous and finger-prick blood: the
PIMA CD4. J Acquir Immune Defic Syndr
2011; 58: e103–e111.
14. Birx D, De Souza M and Nkengasong JN.
Laboratory challenges in the scaling up of
HIV, TB, and malaria programs: The inter-
action of health and laboratory systems,
clinical research, and service delivery. Am J
Clin Pathol 2009; 131: 849–851.
15. MacLennan CA, Van Oosterhout JJG,
White SA, et al. Finger-prick blood samples
can be used interchangeably with venous
samples for CD4 cell counting indicating
their potential for use in CD4 rapid tests.
AIDS 2007; 21: 1643–1645.
16. Sitoe N, Luecke E, Tembe N, et al. Absolute
and percent CD4þ T-cell enumeration by
flow cytometry using capillary blood.
J Immunol Methods 2011; 372: 1–6.
17. Fajardo E, Metcalf C, Piriou E, et al. Errors
generated by a point-of-care CD4þ T-lym-
phocyte analyser: a retrospective observa-
tional study in nine countries. Bull World
Health Organ 2015; 93: 623–630.
18. Bond MM and Richards-Kortum RR.
Drop-to-drop variation in the cellular com-
ponents of fingerprick blood: implications
for point-of-care diagnostic development.
Am J Clin Pathol 2015; 144: 885–894.
19. Mtapuri-Zinyowera S, Chiyaka ET,
Mushayi W, et al. PIMA point of care
CD4þ cell count machines in remote
MNCH settings: Lessons learned from
seven districts in Zimbabwe. Infect Dis
(Auckl) 2013; 6: 51–60.
Vidhyavathi et al. 9
